.
. .

Health care is new front for transgender rights under Trump

.
.
.
.

That question has bedeviled the field of T-cell immunotherapy, even as it has raced into the clinic. Novartis’ Kymriah, approved last year to treat a form of pediatric leukemia, is expected to receive additional federal approval this week to treat an aggressive type of adult lymphoma. Another T-cell therapy, Gilead’s Yescarta, also treats lymphoma.

Now, University of Pennsylvania researchers, who developed Kymriah with drugmaker Novartis, believe they’ve found an explanation for treatment failures — and it shows the still-mysterious variety and interaction of T cells, the soldier blood cells that fight infection and cancer.

.
.